Interim Report – Q1-Q3, 2026

5 November 2026



ViroGates

Forward-looking statements

Certain information set forth and given in this presentation contains "forward-looking information", including "future-oriented financial information" and "financial outlook", under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of ViroGates A/S (ViroGates); (ii) the expected development of ViroGates' business, projects and joint ventures; (iii) execution of ViroGates' vision and growth strategy, including with respect to future M&A activity and global growth; (iv) sources and availability of third-party financing for ViroGates' projects; (v) completion of ViroGates' projects that are currently underway, in development or otherwise under consideration; (vi) renewal of ViroGates' current customer, supplier and other material agreements; and (vii) future liquidity, working capital, and capital requirements.

Forward-looking statements are provided to allow potential investors the opportunity to understand management's beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment.

These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.

Although forward-looking statements contained in this presentation are based upon what management of ViroGates believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. ViroGates undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.

Contents

Summary 4

Management review 9

Financial statements 14

Statement by the Board and Executive Management 23

On 5 November 2026, the Board of Directors approved the interim report for the first nine months of 2026 (the period 1 January – 30 September 2026) for ViroGates A/S.

The interim report is unaudited.

Contents

Summary **4**

Management review 9

Financial statements 14


Statement by the Board and Executive Management 23

Revenue increased by 75% in Q1-Q3 2026, mainly due to large orders from our U.S. partner in the second quarter – with stock now in place, the stage is set for roll-out to end users in the U.S.

Financial results in Q1-Q3 2026

(Q1-Q3 2025 results in brackets)

- Revenue increased by 75% to TDKK 6,212 (TDKK 3,542)
- Operating expenses amounted to TDKK -11,645 (TDKK -12,578)
- Operating loss (EBIT) decreased by 16% to TDKK -6,643 (TDKK -7,904)
- Net loss decreased by 29% to TDKK -5,679 (TDKK -7,961)
- Cash and cash equivalents at the end of the period amounted to TDKK 14,885 (TDKK 9,120)



"Revenue for the first nine months of 2026 was up 75% compared with the same period last year, and operating loss and net loss are both down. As explained in our half-year report, growth was concentrated in Q2, when suPARbio™, our U.S. partner, took delivery of the minimum order under the 2024 distribution agreement. With that stock now in place, Q3 was slower, in line with our expectations. We continue to support suPARbio™ closely and follow the actual roll-out to end users in the U.S. At the same time, our new business-development organization is taking shape to build more scalable partnerships."

Josephine Baum Jørgensen, CFO



Josephine Baum Jørgensen

In Q1-Q3 2026, ViroGates submitted an FDA application with Sobi, advanced suPARnostic® POC+, supported the U.S. roll-out, and reshaped its commercial organization for scalable growth

Business highlights in Q1-Q3 2026

- ViroGates and Sobi submitted the De Novo application to the U.S. FDA for suPARnostic® TurbiLatex in April 2026, for use in combination with Kineret® (anakinra) (cf. Company Announcement No. 3-2026). As anticipated, the FDA has issued a response requesting additional information, and the parties are currently preparing clinical and analytical data in response to the requests. ViroGates held a consultative meeting (Q-Sub meeting) with the FDA on 3 September 2026 to clarify needs for additional data to support the application.
- ViroGates and GENSPEED Biotech moved suPARnostic® POC+ from proof of concept into testing and validation. ViroGates is currently awaiting additional clinical data to assess the viability for regulatory submission.
- ViroGates' U.S. partner, suPARbio™, took delivery of the minimum order under the 2024 distribution agreement, building up stock ahead of a scalable commercial launch. ViroGates continues to support and closely follow the roll-out.
- On 3 August 2026, ViroGates announced a shift toward a business-development model built on larger, more scalable partnerships. Alexandre ("Alex") Delatour joined as VP of Business Development, and Thomas Krarup, VP Global Sales & Marketing, left ViroGates at the end of September (cf. Company Announcement No. 6-2026).
- ViroGates revised its 2026 guidance to revenue of DKK 6.5-8 million, with EBIT maintained at DKK -10 to -12 million (cf. Company Announcement No. 7-2026).
- By the end of Q3 2026, ViroGates reports a recurring customer base of 18 customers (18 at the end of Q3 2025).



The full-year financial guidance for 2026 is maintained at 6.5 to 8 DKKm in revenue and -10 to -12 DKKm in EBIT

Full-year outlook, 2026

- The strategic refocusing of ViroGates continues to progress, although such a transition inherently involves a degree of uncertainty. Longevity-related customers account for a substantial share of revenue in Q1-Q3 2026, but this still largely reflects a single large distribution account rather than broad-based, recurring demand across the segment. ViroGates continues to build a more scalable longevity customer base by targeting laboratories, clinic chains, and new partners specializing in preventive health services.
- In the U.S., suPARbio™ has moved further into the actual roll-out of suPARnostic® to end users, and ViroGates continues to provide support as testing activity builds up. The U.S. longevity, prevention, and population-wide health screening market remains a key market to ViroGates.
- ViroGates continues its collaboration with Sobi to obtain marketing clearance for suPARnostic® TurbiLatex in the U.S. As anticipated, the FDA has requested additional information to the De Novo application submitted in April 2026 (cf. Company Announcement No. 3-2026), and ViroGates and Sobi are currently preparing a response based also on the Q-sub meeting held on 3 September 2026. This work is not expected to have a revenue impact in 2026.
- Following the changes to ViroGates' commercial organization announced on 3 August 2026 (cf. Company Announcement No. 6-2026), the guidance accounts for the implementation of the new structure and personnel during H2 2026.
- The financial guidance for 2026, revised in August (cf. Company Announcement No. 7-2026), is maintained. ViroGates closely monitors financial performance and will update its guidance accordingly.

Full-year guidance, 2026

6.5 to 8 DKKm

revenue in 2026

-10 to -12 DKKm

EBIT in 2026

Contents

Summary 4

Management review 9

Financial statements 14

Statement by the Board and Executive Management 23

In Q1-Q3 2026, ViroGates put its new commercial organization in place, sharpened its partnership-led strategy, and prepared for the next regulatory steps in the U.S. and EU


Jakob Knudsen

From restructuring to partnership-led growth

With our new commercial organization now in place, ViroGates has moved from restructuring to execution. Alexandre ("Alex") Delatour has been onboarded as VP of Business Development and leads our work to build scalable partnerships with players who have direct market access (cf. Company Announcement No. 6-2026).

A central part of this work is a review of our existing partner portfolio. We are assessing where current distributors and partners can take greater ownership of their local markets, and where new partners can help us reach more end users. suPARbio™, our U.S. commercial partner, remains the model for this approach: one partnership designed to reach an entire market, rather than one clinic relationship at a time.

Our ambition is fewer, larger relationships that can scale faster than a traditional clinic by clinic sales model, and we look forward to updating the market as new partnerships materialize.

POC+ for longevity

Together with GENSPEED Biotech, we have completed further testing of the revised suPARnostic® POC+, optimized for the preventive health and longevity market. As a finger-prick test, POC+ can be offered beyond the clinical setting, e.g., at pharmacies and wellness and longevity clinics, widening the population that can access suPAR testing.

We are currently strengthening the clinical documentation to ensure the product configuration is as clinically relevant as possible.

Regulatory progress in the U.S. and EU

In the U.S., we submitted the De Novo application for suPARnostic® TurbiLatex to the FDA together with Sobi in April 2026 (cf. Company Announcement No. 3-2026). As anticipated, the FDA has requested additional information, and the underlying analytical and clinical work to prepare a response is ongoing. We obtained valuable guidance as to the requirements at a Q-Sub meeting on 3 September 2026 and are preparing our final response to the FDA.

In the EU, we are dedicating resources to the transition to the IVDR regulatory scheme. This includes upgrading our ISO systems and technical documentation to prepare for an audit by the Notified Body, which is key to securing our market access in the EU going forward.

Financial highlights

Key figures and ratios

DKK ('000) unless otherwise stated		Q1-Q3, 2026	Q1-Q3, 2025	% change	2025
INCOME STATEMENT	Net revenue	6,212	3,542	75%	5,307
	Other income	224	2,999	-93%	3,597
	Gross profit/loss	5,003	4,674	7%	6,621
	Operating profit/loss (EBIT)	-6,643	-7,904	-16%	-10,472
	Financial income and expenses, net	98	-638	-115%	-757
	Profit/loss for the period before tax	-6,545	-8,542	-23%	-11,229
	Profit/loss for the period	-5,679	-7,961	-29%	-10,397
BALANCE SHEET	Assets	19,095	14,210	34%	30,589
	Equity	13,724	2,835	384%	19,403
	Liabilities	5,371	11,374	-53%	11,186
CASH FLOW STATEMENT	Cash flows from operating activities	-10,543	-2,567	311%	-4,125
	Cash flows from investment activities	0	0	-	5
	Cash flows from financing activities	-869	-520	67%	18,209
	Total cash flows	-11,412	-3,088	270%	14,089


DKK unless otherwise stated	Q1-Q3, 2026	Q1-Q3, 2025	% change	2025
Rate of return (%)	-200.49	-162.41	23%	-290.60
Share price, end of period	8.70	10.10	-14%	13.45
Equity ratio (%)	72%	20%	260%	63%
Employees, end of period (#)	8	7	9%	7

Note: N/A = not meaningful. Percentage changes are not presented where the comparison-period base value is too small to provide a meaningful denominator, as the resulting percentage would not reflect meaningful information about underlying performance.

Financial highlights (continued)


Revenue by product

DKKm, % of total



Revenue by geographic area

DKKm, % of total




Note: Regional split uses the United Nations geoscheme created by the UNSD.

Financial highlights (continued)

Recurring customers by segment

(# by end of period)





Alexandre Delatour

"We are changing how ViroGates grows. Instead of chasing markets, we are building a network of partners who champion suPARnostic® and have everything they need to succeed. The plan is clear, the team is energized, and we are ready to scale."

Alexandre Delatour, VP of Business Development

Note: Recurring customers are customers who have placed at least two orders over the last 12 months with an accumulated value of the orders of > 10,000 EUR. Clinical routine customers refer to customers using suPARnostic® products in routine patient/client handling and processes (e.g. a hospital using suPARnostic® for triage in the ED), while research customers refer to customers using suPARnostic® products for research purposes (e.g. a CRO using suPARnostic® to select patients in clinical trials).

The Annual Report 2026 will be the last report with recurring customers as a KPI, as our strategic shift calls for different measures of progress

Why we are discontinuing the current measure

1

Partners now own local markets

Partners take ownership of an entire market and serve many end users, but each in its own way: some through a few large labs, others through many small clinics below the threshold. The current measure could not capture these differences.

2

Fewer, larger relationships by design

Our strategy targets fewer partnerships that scale faster. Growth can come with a stable or lower customer count, so the current measure risks sending the wrong signal.

3

The definition does not fit large orders

A recurring customer must place two orders within 12 months. A partner building stock through one large order may not qualify, even as our largest account.

4

Small numbers, limited insight

With around 20 customers, which has been stable for the past couple of years, a change of one or two moves the count without saying much about underlying performance.

Going forward

Recurring customers will be reported for the last time in the Annual Report 2026. From 2027, we will continue to report revenue by product and geographic area, and update on progress with our key partners, including roll-out and testing volumes as they materialize.

Contents

Summary 4

Management review 9

Financial statements 14

Statement by the Board and Executive Management 23

Income Statement

PROFIT & LOSS *Amounts in DKK ('000)*	Note	Q3, 2026	Q3, 2025	% change	Q1-Q3, 2026	Q1-Q3, 2025	% change	2025
Net revenue		**1,111**	**1,673**	**-34%**	**6,212**	**3,542**	**75%**	**5,307**
Other income		0	0	N/A	224	2,999	-93%	3,597
Cost of goods/services sold		-418	-614	-32%	-1,433	-1,868	-23%	-2,283
Gross profit		**693**	**1,059**	**-35%**	**5,003**	**4,674**	**7%**	**6,621**
Sales and distribution costs	**1**	-1,214	-1,109	9%	-4,088	-4,067	1%	-5,365
Research and development costs		-1,678	-1,467	14%	-5,462	-6,222	-12%	-8,143
Administrative costs		-501	-516	-3%	-2,095	-2,288	-8%	-3,585
Operating loss (EBIT)		**-2,699**	**-2,033**	**33%**	**-6,643**	**-7,904**	**-16%**	**-10,472**
Financial income		1	3	-53%	421	44	849%	47
Financial expenses		-102	-127	-19%	-323	-682	-53%	-803
Loss before tax		**-2,800**	**-2,157**	**30%**	**-6,545**	**-8,542**	**-23%**	**-11,229**
Tax on profit/loss for the period	**2**	320	228	41%	866	581	49%	832
Loss for the period		**-2,480**	**-1,930**	**29%**	**-5,679**	**-7,961**	**-29%**	**-10,397**
Proposed distribution of loss								
Retained profit		-2,480	-1,930	29%	-5,679	-7,961	-29%	-10,397
Total		**-2,480**	**-1,930**	**29%**	**-5,679**	**-7,961**	**-29%**	**-10,397**

Balance Sheet

ASSETS *Amounts in DKK ('000)*	Note	Q3, 2026	Q3, 2025	% change	2025
Rent deposit and other receivables		196	181	8%	186
Fixed asset investments	**3**	**196**	**181**	**8%**	**186**
Finished goods and goods for resale		1,269	1,795	-29%	1,754
Inventories		**1,269**	**1,795**	**-29%**	**1,754**
Trade receivables		595	1,201	-50%	1,166
Other receivables		133	78	71%	227
Corporation tax receivable		1,698	1,416	20%	832
Prepayments and accrued income		320	418	-24%	128
Receivables		**2,746**	**3,113**	**-12%**	**2,353**
Cash and cash equivalents		**14,885**	**9,120**	**63%**	**26,297**
Current assets		**18,899**	**14,029**	**35%**	**30,403**
Assets		**19,095**	**14,210**	**34%**	**30,589**

EQUITY AND LIABILITIES *Amounts in DKK ('000)*	Note	Q3, 2026	Q3, 2025	% change	2025
Share capital		9,284	7,737	20%	9,284
Retained profit		4,440	-4,902	-191%	10,119
Equity	**4**	**13,724**	**2,835**	**384%**	**19,403**
EIFO loan		2,379	3,634	-35%	3,330
Non-current liabilities		**2,379**	**3,634**	**-35%**	**3,330**
EIFO loan		1,258	1,145	10%	1,293
Trade payables		960	654	47%	632
Other liabilities		775	5,941	-87%	5,931
Current liabilities		**2,993**	**7,740**	**-61%**	**7,856**
Liabilities		**5,371**	**11,374**	**-53%**	**11,186**
Equity and liabilities		**19,095**	**14,210**	**34%**	**30,589**
Contingencies	**5**				

Cash Flow Statement

CASH FLOW *Amounts in DKK ('000)*	Note	Q3, 2026	Q3, 2025	% change	Q1-Q3, 2026	Q1-Q3, 2025	% change	2025
Profit/loss for the period		-2,480	-1,930	29%	-5,679	-7,961	-29%	-10,397
Reversed tax on profit/loss for the period		320	-228	-241%	866	-581	-249%	3
Corporation tax received		0	0	-	0	0	-	835
Change in inventory		182	577	-68%	486	1,016	-52%	1,057
Change in receivables		49	440	-89%	-403	623	-165%	544
Change in current liabilities (ex bank and tax)		-526	-1,352	-61%	-5,812	4,336	-234%	3,833
Cash flows from operating activity		**-2,454**	**-2,492**	**-2%**	**-10,543**	**-2,567**	**311%**	**-4,125**
Purchase of tangible fixed assets		0	0	-	0	0	-	0
Purchase of financial assets		0	0	-	0	0	-	5
Cash flows from investing activity		**0**	**0**	**-**	**0**	**0**	**-**	**5**
Subscription of share capital		0	0	-	0	0	-	19,005
Loan		-296	-266	12%	-869	-520	67%	-795
Cash flows from financing activity		**-296**	**-266**	**12%**	**-869**	**-520**	**67%**	**18,209**
Change in cash and cash equivalents		-2,750	-2,757	-	-11,412	-3,088	270%	14,089
Cash and cash equivalents at 1 July/1 January		17,635	11,878	48%	26,297	12,208	115%	12,208
Cash and cash equivalents at end of period		**14,885**	**9,120**	**63%**	**14,885**	**9,120**	**63%**	**26,297**
Specification of cash and cash equivalents at end of period:								
Cash and cash equivalents		14,885	9,120	63%	14,885	9,120	63%	26,297
Cash and cash equivalents		**14,885**	**9,120**	**63%**	**14,885**	**9,120**	**63%**	**26,297**

Notes to the financial statements

1 Staff costs

Amounts in DKK ('000) unless otherwise stated	Q3, 2026	Q3, 2025	% change	2025
Average number of employees (#)	8	7	9%	7
Sales & Marketing	915	809	13%	3,761
Research & Development	604	528	14%	2,456
Administration	311	314	-1%	1,458
Total staff costs	**1,830**	**1,650**	**11%**	**7,676**

The remuneration for the Board of Directors and Executive Management are published annually in the Company's Remuneration Report in connection with the Annual Report.

2 Tax on profit/loss for the period

Amounts in DKK ('000)	Q3, 2026	Q3, 2025	% change	2025
Calculated tax on taxable income	320	228	41%	832
Total	**320**	**228**	**41%**	**832**

3 Fixed asset investments

Amounts in DKK ('000)	Q3, 2026	Q3, 2025	% change	2025
Rent deposit and other receivables				
Cost at 1 July 2026 / 2025	186	181	3%	181
Additions	**10**	**0**	**-**	**5**
Cost at Q3 2026, Q3 2025, 2025	**196**	**181**	**8%**	**186**
Carrying amount of Q3 2026, Q3 2025, 2025	**196**	**181**	**8%**	**186**

Notes to the financial statements (continued)

4 Equity

Amounts in DKK	Q3, 2026	Q3, 2025	% change	2025
Share capital	9,284,476	7,737,064	20%	7,737,064
Retained profit	10,118,599	3,058,415	231%	3,058,415
Equity at 1 July	**19,403,075**	**10,795,479**	**80%**	**10,795,479**
Capital increase (share capital)	0	0	-	1,547,412
Capital increase (retained profit)	0	0	-	17,717,867
Cost regarding capital increase	0	0	-	-260,741
Proposed distribution of loss to retained profit	-5,678,962	-7,960,563	-29%	-10,396,943
Equity end of period	**13,724,112**	**2,834,916**	**384%**	**19,403,075**

The Company's share capital consists of 9,284,476 shares of nom. 1 kr.

The Company has 2,585 treasury shares of nom. 1 kr. which equals 0.03% of the total share capital.

Under a resolution passed by the General Meeting, the Company may acquire treasury shares up to 10% of the share capital.

5 Contingencies

The Company has provided a guarantee in the form of a bank deposit of DKK ('000) 50 as security for all balances with Danske Bank.

6 Other external expenses

Amounts in % of total expenses	Q3, 2026	Q3, 2025	% change	2025
Sales expenses (incl. staff) in % of total expenses	35.8%	35.9%	0%	31.4%
R&D expenses (incl. staff) in % of total expenses	49.4%	47.4%	4%	47.6%

Active management & board warrant programs (as of 30 September 2026)

2019 warrant program

Warrants (#, % of total)	Warrants allocated	Warrants exercised	Warrants expired	Warrants outstanding (vested)	Warrants outstanding (total)
Jakob Knudsen (CEO)	56,439 (100%)	13,253 (23%)	16,931 (30%)	26,255 (47%)	26,255 (47%)
Jesper Eugen-Olsen (CSO)	8,084 (100%)	5,051 (62%)	0 (0%)	3,033 (38%)	3,033 (38%)

2019 program details

- Strike price at 35 DKK
- 12% annual price increase from vesting date
- Expiry five years from vesting date

2022 warrant program

Warrants (#, % of total)	Warrants allocated	Warrants exercised	Warrants expired	Warrants outstanding (vested)	Warrants outstanding (total)
Other employees	12,500 (100%)	0 (0%)	0 (0%)	12,500 (100%)	12,500 (100%)
Patrik Dahlen (Chairman)	31,700 (100%)	0 (0%)	0 (0%)	31,700 (100%)	31,700 (100%)
Valérie Soulier (BM)	9,510 (100%)	0 (0%)	0 (0%)	9,510 (100%)	9,510 (100%)
Josephine Baum (CFO)	30,000 (100%)	0 (0%)	0 (0%)	25,500 (85%)	30,000 (100%)

2022 program details

- Strike price at 129 DKK (other employees), 57.8 DKK (BoD), and 49.50 DKK (CFO)
- 12% annual price increase from vesting date
- Expiry five years from vesting date

2025 warrant program

Warrants (#, % of total)	Warrants allocated	Warrants exercised	Warrants expired	Warrants outstanding (vested)	Warrants outstanding (total)
Jakob Knudsen (CEO)	55,000 (100%)	0 (0%)	0 (0%)	20,625 (38%)	55,000 (100%)
Jesper Eugen-Olsen (CSO)	30,000 (100%)	0 (0%)	0 (0%)	11,250 (38%)	30,000 (100%)
Josephine Baum (CFO)	15,000 (100%)	0 (0%)	0 (0%)	9,375 (38%)	15,000 (100%)
Other employees	5,000 (100%)	0 (0%)	0 (0%)	1,875 (38%)	5,000 (100%)

2025 program details

- Strike price at 13 DKK
- 12% annual price increase from vesting date
- Expiry five years from vesting date

Note: Numbers may not add up due to rounding. Thomas Krarup (previous VP Global Sales and Marketing) has 18,470 outstanding warrants in the 2019 and 2025 warrant programs. A group of employees no longer employed by ViroGates still has 14,867 outstanding warrants in total across the 2019 and 2022 programs. The 2015 warrant program is not listed above, as all non-exercised warrants in the program have expired.


Shareholdings of the board and management

Management (role)	Executive Management[1]	Management	PDMR[2]	Shares (#, end of Q3, 2026)	Shares (#, end of Q2, 2026)	Shares (#, end of last year)
Jakob Knudsen (CEO)	Yes	Yes	Yes	118,914	118,914	118,914
Josephine Baum Jørgensen (CFO)	No	Yes	Yes	1,200	1,200	1,200
Jesper Eugen-Olsen (CSO)	No	Yes	No	312,540	304,205	301,558
Alexandre Delatour[3] (VP of Business Development)	No	Yes	Yes	0	N/A	N/A

Board (role)	PDMR[2]	Shares (#, end of Q3, 2026)	Shares (#, end of Q2, 2026)	Shares (#, end of last year)
Patrik Dahlen (Chairman)	Yes	10,570	10,570	10,570
Lars Kongsbak (Board member)	Yes	6,968	6,968	6,968
Valérie Soulier (Board member)	Yes	0	0	0

Note: 1) Executive management registered with the Danish Business Authority; 2) Person Discharging Managerial Responsibilities (permanent insider with access to all information); 3) Alexandre Delatour joined ViroGates as VP of Business Development in August 2026. Thomas Krarup, previously VP Global Sales & Marketing, left ViroGates on 30 September 2026.

Trading windows for persons discharging managerial responsibilities



Trading windows for PDMRs

- **Closed periods:** In accordance with MAR, ViroGates has a closed period of 30 days before the announcement of an interim financial report or a year-end report
- **Open periods:** ViroGates has an open period of six weeks after the announcement of an interim financial report or a year-end report (if an open period of a previous report overlaps a closed period of an upcoming report, the closed period applies)

Note: PDMRs can only trade shares during open trading windows given no insider information at the time of trading.

Contents

Summary 4

Management review 9

Financial statements 14

Statement by the Board and Executive Management 23

Statement by the Board of Directors and Executive Management

Statement

Today, the Board of Directors and the Executive Management have discussed and approved the Interim Report of ViroGates A/S for the first nine months of 2026 (1 January – 30 September 2026).

The interim report has been created in accordance with IAS 34, Interim Financial Reporting as approved by the EU and additional disclosure requirements for companies listed on NASDAQ First North Denmark.

In our opinion, the financial statements give a true and fair view of the company's financial position on 30 September 2026 and of the results of the company's operations and cash flows for the financial period 1 January – 30 September 2026.

The management's review includes, in our opinion, a fair presentation of the matters dealt with in the report.

The interim report is unaudited.

Birkerød, 5 November 2026

Executive Management

Jakob Ole Knudsen
CEO

Board of Directors

Patrik Dahlen
(Chairman)

Valérie Soulier

Lars Kongsbak